MindMed's stock jumped 6.4% on a day when the rest of the psychedelic sector barely moved, which strongly suggests someone with inside knowledge was buying in advance of good news. Within four weeks, the company is expected to announce what that news is — likely a milestone in one of their drug trials, a new round of funding, or a partnership with a larger company.
A 6% single-name move decoupled from peers is rarely random. Institutional accumulation ahead of a known event is the base case.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →